Scienture (NASDAQ:SCNX – Get Free Report) is projected to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($1.57) per share and revenue of $1.22 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 4:00 PM ET.
Scienture (NASDAQ:SCNX – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.25) by $2.18. The firm had revenue of $0.34 million for the quarter, compared to analyst estimates of $1.96 million. On average, analysts expect Scienture to post ($4.44) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.
Scienture Stock Performance
Shares of NASDAQ SCNX opened at $3.20 on Tuesday. Scienture has a 52-week low of $2.64 and a 52-week high of $19.47. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.97 and a current ratio of 3.04. The company’s 50 day moving average price is $5.49 and its 200-day moving average price is $8.93.
Wall Street Analyst Weigh In
View Our Latest Analysis on SCNX
About Scienture
Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for central nervous system disorders. The company seeks to address unmet treatment needs through pharmaceutical products and drug-delivery technologies designed to improve patient convenience and therapeutic use.
Scienture’s areas of interest include conditions such as insomnia, attention-deficit/hyperactivity disorder, anxiety, depression and pain. Its portfolio includes product candidates and commercial opportunities involving alternative delivery formats, including oral formulations and sprays.
The company serves the pharmaceutical market primarily in the United States.
Read More
- Five stocks we like better than Scienture
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
